Skip to main content
. 2022 Jun 22;8(25):eabn7162. doi: 10.1126/sciadv.abn7162

Fig. 5. Biodistribution of siIL11@PPGC NPs in the lungs of bleomycin-induced fibrosis mice after nebulization.

Fig. 5.

(A) Schematic illustration of the vibrating mesh nebulizer device. (B) IVIS imaging of lungs and other organs including heart, liver, spleen, and kidney collected at 24 hours after nebulization of Cy5.5-labeled siIL11@PPGC NPs. Organs from the mice that received PBS treatment were imaged as control. Fluorescence could be observed in all five lobes (N = 3). (C) Quantitative analysis of fluorescence signal in left, cranial, middle, caudal, and accessory lobes (N = 3). (D and E) Subcellular localization of siIL11@PPGC NPs analyzed by flow cytometry (D) and its quantitative assessment (E). Different cell subtypes were marked with corresponding antibodies including anti-CD31 (endothelial), anti-EpCAM (epithelial), and anti-CD45 (immune) (N = 3). Significant differences were assessed using a two-tailed unpaired Student’s t test. Results are presented as means ± SD. **P < 0.01, n.s., not significant, P > 0.05.